
EXPERT REACTION: Gut risks linked to group of diabetes/weight loss drugs that includes Ozempic
Observational study: A study in which the subject is observed to see if there is a relationship between two or more things (eg: the consumption of diet drinks and obesity). Observational studies cannot prove that one thing causes another, only that they are linked.
Opinion piece/editorial: This work is based on the opinions of the author(s)/institution.
People: This is a study based on research using people.
A family of diabetes drugs that includes Ozempic is associated with an increased risk of gastrointestinal issues, according to international research. The team used information from a health database to compare potential side effects of glucagon-like peptide 1 agonists liraglutide and semaglutide (Ozempic) with bupropion-naltrexone (Contrave), an obesity medication. The researchers say semaglutide and liraglutide were associated with increased risks of pancreatitis, gastroparesis and bowel obstruction. Below, Australian experts discuss the findings.
Attachments:
Note: Not all attachments are visible to the general public
News for:
Australia
International
NSW
VIC
SA
Media contact details for this story are only visible to registered journalists.
Expert Reaction
These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.
Dr Georgia Rigas is a VMO-Obesity Doctor & Senior Bariatric Medical Practitioner at St George Private Hospital, Kogarah and consulting also at Cronulla. She is the founder & past chair of the RACGP Obesity Management Network